# Safety, Tolerability and Pharmacokinetics (PKs) Investigation of GSK3186899 in Healthy Subjects

> **NCT03874234** · PHASE1 · TERMINATED · sponsor: **GlaxoSmithKline** · enrollment: 25 (actual)

## Conditions studied

- Leishmaniasis

## Interventions

- **DRUG:** GSK3186899
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03874234
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-04-30
- **Primary completion:** 2019-10-17
- **Final completion:** 2019-10-17
- **Target enrollment:** 25 (ACTUAL)
- **Why stopped:** The trial was terminated early following strategic review after emergence of nonclinical data with a non-GlaxoSmithKline asset.
- **Last updated:** 2023-02-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03874234

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03874234, "Safety, Tolerability and Pharmacokinetics (PKs) Investigation of GSK3186899 in Healthy Subjects". Retrieved via AI Analytics 2026-07-11 from https://api.ai-analytics.org/clinical/NCT03874234. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*